Endorsements (en inglés)

What people are saying about the MPP


… from the international community












Dr. Margaret Chan, WHO Director-General, opening remarks at a joint WHO/WIPO/WTO technical symposium on public health, intellectual property and TRIPS at 20 –  WHO Director-General addresses symposium on intellectual property and trade, 28 October 2015


“UNITAID applauds today’s agreement by ViiV and the MPP to address the specific needs of children living with HIV,” said Philippe Douste Blazy, Chair, UNITAID. “Incorporating palatable, child-friendly medicine options into paedriatic HIV programmes could significantly enhance and prolong children’s lives.”  – UNITAID’s statement, 1 April 2014

“The Joint United Nations Programme on HIV/AIDS (UNAIDS) welcomes the new collaboration between the Medicines Patent Pool and ViiV Healthcare to increase access to antiretroviral therapy for children. The new agreement is a significant step forwards in HIV treatment for children as very few antiretroviral drugs are formulated for paediatric use. In 2012 UNAIDS estimated that 72% of children living with HIV who were eligible for treatment did not have access.” – UNAIDS press statement, 28 February 2013

“I commend UNITAID for taking the initiative to establish the Medicines Patent Pool. The WHO Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property recognized early on the potential of such voluntary mechanisms. Recently the G8 encouraged patent-holders to participate in the Medicines Patent Pool. I admire the companies that are in negotiations with the Patent Pool, and the US NIH for having been the first to license to the Pool… Let us accelerate the two-pronged innovation that has been the hallmark of the HIV response: innovation to deliver existing interventions and innovation for new tools to do more.”- Margaret Chan, Executive Director of the World Health Organization, Introductory remarks at the 2011 High-level meeting on AIDS, 9 June 2011

“Voluntary use, where appropriate, of … patent pools benefiting all developing countries, including through entities such as the Medicines Patent Pool, [is encouraged] to help reduce treatment costs and encourage development of new HIV treatment formulations, including HIV medicines and point-of-care diagnostics, in particular for children.” – United Nations General Assembly Political Declaration on HIV/AIDS, June 2011


… from national governments

“Of the 3.2 million children with HIV in the world, more than 90% live in sub-Saharan Africa with South Africa bearing a significantly high burden. (…) New adapted treatments of LPV/r and other medicines are urgently needed to end the HIV paediatric crisis. We are thus very pleased with the agreement signed today.” – South African Minister of Health, Aaron Mostoaledi, commenting the MPP-AbbVie licence agreement for lopinavir/ritonavir paediatric treatment, 1 December 2014

“On the occasion of World AIDS Day, France expresses its solidarity with the 35 million people living with HIV. It welcomes the signing – announced today – of a new agreement between the Medicines Patent Pool and the laboratory AbbVie. This will provide access, at an affordable price, to antiretroviral drugs for children (lopinavir/ritonavir).” – French Ministry of Foreign Affairs and International Development, 01 December 2014




“The Obama Administration is committed to increasing access to medicines and supporting innovation for the development of new and improved drugs for HIV/AIDS and other diseases. This week’s announcement of an agreement between ViiV Healthcare (a joint venture of GlaxoSmithKline, Pfizer, and Shionogi) and the Medicines Patent Pool marks a significant step forward in ongoing efforts to achieve both access to medicines for developing countries and the promotion of innovation to develop more of these life-saving treatments. (…) The National Institutes of Health, Gilead Sciences, Bristol-Myers Squibb, Roche, and ViiV Healthcare have all made strong contributions to the success of the Medicines Patent Pool. As the Medicines Patent Pool continues to grow, adding industry partners and access to their life-saving medicines, we look forward to celebrating future voluntary arrangements, and the concrete steps we are taking together towards President Obama’s shared vision of an AIDS-free generation.” – The White House Blog, 04 April 2014


… from civil society and communities of people living with HIV

“This is an important milestone in the treatment of hepatitis C and we congratulate BMS and the MPP on their agreement to bring essential medicines to low- and middle-income countries at affordable prices. Going forward we urge the MPP and other pharmaceutical companies to include more hepatitis C medicines in the patent pool in order to eliminate one of the world’s leading health concerns,” said Raquel Peck, CEO of World Hepatitis Alliance–  23 November 2015


“The Ecumenical Advocacy Alliance (EAA) applauds the licensing agreement announced on 1 December by the Medicines Patent Pool (MPP) and AbbVie for the drugs lopinavir (LPV) and ritonavir (r), top World Health Organization-recommended medicines for children. (…) “This is a major breakthrough which we have been waiting for a long time,” Berner-Rodoreda stated. “It will simplify the HIV treatment for small children and ensure that pediatric formulations will become more appropriate for developing countries.” –  Ecumenical Advocacy Alliance, 03 December 2014

“UAEM welcomes the announcement of the licensing agreement between the Medicines Patent Pool and AbbVie. (…) This agreement is good news for children who are still sorely neglected in the global fight against HIV with currently fewer than a quarter on treatment. UAEM sees this as an important first step.” – Universities Allied for Essential Medicines, 01 December 2014

“The All Ukrainian Network of People living with HIV/AIDS welcomes the announcement as highly important for children living with HIV in Ukraine: ‘We are delighted that ViiV has reacted positively to our request and has included Ukraine into the MPP licence for paediatric abacavir, an important medicine for children living with HIV.  Given the current situation in Ukraine, initiatives that result in access to lower priced ARVs are particularly important.’ “- All Ukranian Network of People living with HIV/AIDS, 26 November 2014

“The MPP has been an important advocacy organisation in supporting people living with HIV around the world.”- Suzette M. Moses-Burton, Executive Director, Global Network of People Living with HIV, October 2014 

“The MPP is a critical addition to the struggle against HIV, particularly in support of women and children living with HIV, a particularly vulnerable population.” – Rebecca Matheson, Global Director, International Community of Women Living with HIV, October 2014

“With only one in four children living with HIV currently getting treatment, we cannot continue to do business as usual” (…). “We congratulate MPP and Gilead on this expanded collaboration and their proactive efforts to support countries and populations hardest hit by HIV and AIDS. This is the kind of innovative action that we need now to protect the health of affected children and in order to achieve an AIDS-free generation.” –  Charles Lyons, Elizabeth Glaser Pediatric AIDS Foundation’s President and CEO, 25 July 2014

HAI Europe DTG tweet

“Members of the Interfaith Center on Corporate Social Responsibility (ICCR) and shareholders are applauding ROche on its recent agreement with the Medicines Patent Pool (MPP). (…) Shareholders consider the MPP to be an important program to help address the access to medicines issues thus facilitating efforts of pharmaceutical companies to meet their moral obligation to the health needs of the world’s most vulnerable.” – Interfaith Center on Corporate Social Responsibility (ICCR),  27 August 2013


… from companies and product development partners

“The Drugs for Neglected Diseases initiative (DNDi) welcomes the Medicines Patent Pool announcement this World AIDS Day that it has negotiated an agreement with AbbVie, which is placing two key paediatric HIV medicines, lopinavir andritonavir, into the Pool. ‘With intellectual property barriers formally lifted from lopinavir and ritonavir, the two key components of the World Health Organization’s recommended first-line antiretroviral regimen for paediatrics, more children with HIV will be able to access improved formulations more rapidly’, said Dr Marc Lallemant, Head of the Paediatric HIV Programme at DNDi. ‘This is particularly the case for South Africa, where children are given the current liquid formulation that has an unbearable taste, is full of alcohol, and is difficult for caregivers to administer.’” – Drugs for Neglected Diseases initiative – 01 December 2014


“We consider our partnership with MPP to be crucial to the company’s mission of bridging research and access, and are putting additional resources into ensuring more PLHIV have the medicines they need” – Bhavesh Shah, Director of International Marketing, Hetero Drugs Limited – 25 September 2014

“The MPP is an innovative mechanism for increasing access to both patented pipeline and existing medicines” (…)  Our three-year collaboration has been very successful thus far. Countries eligible for generic competition for TDF, for example, have increased dramatically to the ultimate benefit of many national treatment programmes in key resource-limited countries.” – Gregg Alton, Executive Vice President, Corporate and Medical Affairs for Gilead Sciences, upon signing the licence agreement with the MPP for TAF,  25 July 2014

“We are excited about both the public health and business opportunities provided by the Patent Pool licences. Aurobindo looks forward to increasing its manufacture of HIV-related products, and expanding its work to cover promising new treatments, for the millions of people living with HIV across the globe.” – P.V. Ramaprasad Reddy, Chairman Aurobindo, upon signing a sub-licence agreement with the MPP

This page is also available in: Inglés, Francés